In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BioMimetic Therapeutics, Inc.

http://www.biomimetics.com

Latest From BioMimetic Therapeutics, Inc.

Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Coronavirus COVID-19 Generic Drugs

FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls

Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.

Manufacturing Quality

FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs

Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.

Manufacturing Quality

Lupin And Mylan Launch Etanercept in Germany

In partnership with Lupin, Mylan introduces Nepexto (etanercept) to the German market. After adalimumab, Nepexto is Mylan’s second immunology product in Germany.

Germany Biosimilars
See All

Company Information

UsernamePublicRestriction

Register